Literature DB >> 4000199

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

A R Feinstein, D M Sosin, C K Wells.   

Abstract

We found that a cohort of patients with lung cancer first treated in 1977 had higher six-month survival rates for the total group and for subgroups in each of the three main TNM stages (tumor, nodes, and metastases) than a cohort treated between 1953 and 1964 at the same institutions. The more recent cohort, however, had undergone many new diagnostic imaging procedures. According to the "old" diagnostic data for both cohorts, the recent cohort had a prognostically favorable "zero-time shift." In addition, by demonstrating metastases that had formerly been silent and unidentified, the new technological data resulted in a stage migration. Many patients who previously would have been classified in a "good" stage were assigned to a "bad" stage. Because the prognosis of those who migrated, although worse than that for other members of the good-stage group, was better than that for other members of the bad-stage group, survival rates rose in each group without any change in individual outcomes. When classified according to symptom stages that would be unaltered by changes in diagnostic techniques, the two cohorts had similar survival rates.

Entities:  

Mesh:

Year:  1985        PMID: 4000199     DOI: 10.1056/NEJM198506203122504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  314 in total

1.  Evidence for the Will Rogers phenomenon in migration of employees to managed care plans.

Authors:  M J Young; J Lenhart; T E Wasser; C Czerwonka; J Davidyock; E J Sussman
Journal:  J Gen Intern Med       Date:  1999-09       Impact factor: 5.128

2.  Cancer survival in Britain. Cancer chemotherapy costs money.

Authors:  P G de Takats
Journal:  BMJ       Date:  1999-12-11

3.  [Postoperative radiotherapy in curatively resected non-small-cell bronchial carcinoma].

Authors:  H T Klages; M Stuschke
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

Review 4.  Clinical trials in head injury.

Authors:  Raj K Narayan; Mary Ellen Michel; Beth Ansell; Alex Baethmann; Anat Biegon; Michael B Bracken; M Ross Bullock; Sung C Choi; Guy L Clifton; Charles F Contant; William M Coplin; W Dalton Dietrich; Jamshid Ghajar; Sean M Grady; Robert G Grossman; Edward D Hall; William Heetderks; David A Hovda; Jack Jallo; Russell L Katz; Nachshon Knoller; Patrick M Kochanek; Andrew I Maas; Jeannine Majde; Donald W Marion; Anthony Marmarou; Lawrence F Marshall; Tracy K McIntosh; Emmy Miller; Noel Mohberg; J Paul Muizelaar; Lawrence H Pitts; Peter Quinn; Gad Riesenfeld; Claudia S Robertson; Kenneth I Strauss; Graham Teasdale; Nancy Temkin; Ronald Tuma; Charles Wade; Michael D Walker; Michael Weinrich; John Whyte; Jack Wilberger; A Byron Young; Lorraine Yurkewicz
Journal:  J Neurotrauma       Date:  2002-05       Impact factor: 5.269

Review 5.  [R1 resection in rectal cancer].

Authors:  H-R Raab
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

6.  History of bias.

Authors:  Paolo Vineis
Journal:  Soz Praventivmed       Date:  2002

Review 7.  Evaluating prognostic factors: implications for measurement of health care outcome.

Authors:  M C Gulliford
Journal:  J Epidemiol Community Health       Date:  1992-08       Impact factor: 3.710

Review 8.  Colorectal cancer and lymph nodes: the obsession with the number 12.

Authors:  Giovanni Li Destri; Isidoro Di Carlo; Roberto Scilletta; Beniamino Scilletta; Stefano Puleo
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

9.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

10.  Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Gaurav Marwaha
Journal:  Lung       Date:  2018-03-17       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.